

Pangenomic study in patients with persistent polyclonal binucleated B-cell lymphocytosis (PPBL)

CometE^{1,2}, Courlet³, Lesesve JF⁴, Troussard X^{1,2}, Mossafa H³
 Biologique, CHU Nancy-Brabois, VANDOEUVRE LES NANCY, FRANCE.
 Laboratoire CERBA
 CHU Caen
 Laboratoire CERBA


1. Laboratoire d'Hématologie, CHU Côte de Nacre, CAEN, FRANCE; 2. Université de Caen Basse-Normandie, UPRES EA3319, CAEN, FRANCE; 3. Laboratoire Cerba, Département Génétique, CERBY PONTOISE, FRANCE; 4. Service d'Hématologie Biologique, CHU Nancy-Brabois, VANDOEUVRE LES NANCY, FRANCE.

Background


Initially described in 1982 (1), Persistent Polyclonal B-cell Lymphocytosis (PPBL) is a chronic, stable, persistent and polyclonal B-cell lymphocytosis observed more often in women (62% of patients), with a median age of 40 years and smokers in 98% of cases (2). Physical examination is usually within normal limits, except for a mild splenomegaly in 10% of cases. A polyclonal increase in serum immunoglobulin M (IgM) is associated.

PPBL is diagnosed when blood smear analysis revealed the presence of binucleated lymphocytes, whatever the lymphocyte count. At time of diagnosis, 83% of patients present with mild lymphocytosis with a lymphocyte count over 4x10⁹/L (median at 5.45x10⁹/L, range 2.45-20.52x10⁹/L).


Blood smear analysis revealed the presence of binucleated lymphocytes in the peripheral blood (median=4%, range 1-40%)



Multiparameter flow cytometry showed an expansion of the CD19+ CD5+ B lymphocytes pool. Both kappa and lambda light chain are expressed, confirming the B-cell polyclonal expansion. Polyclonality has been confirmed by immunocytochemistry and by molecular clonality analysis (analysis ofIGHV gene rearrangements by PCR).



We identified a cytogenetic profile by conventional cytogenetic analysis (CCA) and FISH (3). Supernumerary isochromosome 3q, +1(3)(q10), is observed in 71% of PPBL cases. Moreover, cytogenetic instability is often observed (4).



Objective

Our purpose is to study cytogenetic abnormalities in PPBL with a high resolution pangenomic method based on the lastDNA chips technology.

Materials & Methods

Peripheral blood from 7 patients with typical PPBL was analyzed.

After separation of blood leukocytes by Ficoll gradient, we performed immunomagnetic sorting (Miltenyi™ AutoMACS Pro Separator®) of CD19+ B-cells versus CD19- non-B-cells.

DNA extraction was proceeded on the two sorted fraction and hybridization on Affymetrix™ Cytogenetics Whole Genome 2.7M Arrays® was performed according the manufacturer's recommendations.

Data analysis was then performed with Chromosome Analysis Suite® (ChAS®) software using the following settings. Copy number aberrations (gains and losses) and mosaicism were defined when a minimum of 50 copy number (CN) markers corresponding in a size of more than 25 kilobases (kb) were detected. Gene copy number (GCN) aberrations were compared with the Database of Genomic Variants (DGV, <http://projects.tcag.ca/variation/>) to study only non variant GCN aberrations.

Patient	Age	Sex	Number of Recurrent Aberrations	GCN	Aberrations
1	58	F	4	+50(%) / -25(%)	CD19+ CD19-
2	68	M	1	+50(%)	CD19+ CD19-
3	44	F	4	+50(%)	CD19+ CD19-
4	51	F	4	+50(%)	CD19+ CD19-
5	42	M	4	+50(%) / -25(%)	CD19+ CD19-
6	48	F	4	+50(%)	CD19+ CD19-
7	47	F	4	+50(%) / -25(%)	CD19+ CD19-

Results

Recurrent aberrations

The most recurrent GCN gains were detected on the long arm of chromosome 3 (3q), only in CD19+ B cells (5/6 patients). We identified GCN aberrations for all the cells on 3q or non consecutive genes. We also observed mosaicism phenomenon on 3q (gain) for 2 patients.


Other recurrent GCN aberrations were observed, 5 on Xp (3 patients) and 16 on 6q (2 patients).

Non recurrent aberrations

Non recurrent GCN aberrations involved the whole genome, except chromosomes 5 and 22.

One gene were frequently amplified on 3q, only in CD19+ B-cells

MDS1 and *EWI1* complex locus (*MECOM*) was amplified in 5/6 patients, with a common minimal amplified sequence (28 kb, 85 CN markers) of *MECOM* concerning exon 2 of *MDS1*.



Discussion

Our aim was to study genetic abnormalities observed in PPBL. Since +1(3)(q10) has been described as the cytogenetic profile of PPBL, we focused our study on aberrations detected on 3q.

+1(3)(q10) identified by CCA is not a true complete duplication of 3q. The presence of recurrent GCN amplifications is restricted to CD19+ B-cells. Most recurrent GCN aberrations concerned the long arm of chromosome 3 and a few aberrations chromosomes 6q and Xp.

Interestingly, *MECOM* gene, implicated in myeloid malignancies, was totally or partially amplified, with a common minimal amplified sequence of 28 kb implicating exon 2 of *MDS1*. We are getting *MDS1* quantitative PCR to confirm our observations.

Genetic instability in PPBL is confirmed by pangenomic study, particularly the occurrence of non recurrent GCN aberrations involving the whole genome, requiring a long term follow-up of PPBL patients.

The impact of *MECOM* abnormalities (overexpression, rearrangement) is clearly identified in myeloid malignancies but remains to be clarified in lymphoid malignancies.

References

1. Gordon DB et al. (1982). Persistent polyclonal lymphocytosis of B lymphocytes. *N Engl J Med*
2. Comes E et al. (2008). Long-term follow-up of 111 patients with persistent polyclonal B-cell lymphocytosis with binucleated lymphocytes. *Leukemia*
3. Comes E et al. (2008). Polyclonal lymphocytosis with binucleated lymphocytes. *Leuk Lymphoma*
4. Mossafa H et al. (2004). Chromosomal instability and ATRX amplification gene in patients with persistent and polyclonal B-cell lymphocytosis (PPBL). *Leuk Lymphoma*